Clinical Trials Sector Scorecard - Q1 2022 Update - Thematic Research
ページ情報: 英文 18 Pages
Artificial Intelligence, Virtual Care, and Blockchain Saw Activity in Q1 2022. Many companies included in the Clinical Trials scorecard have announced partnerships in the artificial intelligence (AI) space since December 2021. Pfizer announced partnerships in drug discovery and disease severity scoring, while Thermo Fisher Scientific announced that it was partnering with Medidata Acorn AI to optimize clinical trials. Merck KGaA is collaborating with Unlearn.AI to accelerate late-stage trials using AI-based digital twins. In virtual care, Takeda posted several jobs relating to virtual trials and initiated trials with virtual components in Q1 2022, and AstraZeneca, Novo Nordisk, and Otsuka were active in digital health deals. Takeda posted several jobs relating to blockchain in Q1 2022, and Dr. Reddy's is partnering with academia to build a new blockchain solution.
Companies Were Also Active in ESG Initiatives, Driven in Part By the Ukraine Crisis. While there were no significant changes to Environmental, Social, and Governance (ESG) scores in Q1 2022, several interesting events occurred. Samsung Bioepis released its first annual sustainability report, and in March 2022 Zydus Cadila announced that it was to acquire a stake in AMP Energy Green Nine, a move that is in line with its commitment to enhance its use of renewable power. AstraZeneca announced that it was developing inhalers that use a more environmentally friendly propellant, HFO-1234ze, and it was also reported that AstraZeneca China employees were being investigated for suspected medical insurance fraud. Many pharma companies have responded to the Ukraine crisis by donating essentials medicines, medical supplies, and financial support to non-governmental organizations (NGOs).